期刊文献+

焦亡在心肌缺血再灌注损伤中的作用及相关治疗药物研究进展

The Role of Pyroptosis in Myocardial Ischemia-reperfusion Injury and the Research Progress of Related Therapeutic Drugs
下载PDF
导出
摘要 细胞焦亡是近几年来通过研究发现的由半胱天冬氨酸特异性蛋白酶介导Gasdermin D蛋白发挥作用,引发的新的程序性促炎类型细胞坏死,在形态和病理生理上均不同于其它形式的细胞死亡(如凋亡、坏死)。最新研究表明,细胞焦亡参与心肌缺血再灌注损伤(MIRI)。MIRI是急性心肌梗死(AMI)患者经积极血运重建后仍有较高死亡率发生的首要原因之一。部分基于细胞焦亡相关信号通路的药物,在保护心血管疾病模型中发挥了特定作用。本文主要对细胞焦亡在MIRI中的病理生理机制及相关治疗药物影响细胞焦亡并应用于MIRI防治方面进行综述。 In recent years,it has been discovered that pyroptosis is a new programmed pro-inflammatory type of cell necrosis triggered by cysteinyl-specific proteinase(Caspase)mediating the action of Gasdermin D(GSDMD)protein.It differs from other forms of cell death(such as apoptosis and necrosis)in morphologically and pathophysiologically.Recent studies have shown that pyroptosis is involved in myocardial ischemia-reperfusion injury(MIRI),which is one of the main reasons for leading causes of high mortality in patients with myocardial infarction despite aggressive hemodialysis.Some drugs based on the pyroptosis related signaling pathway,exerted specific effects in protecting cardiovascular disease models.This article mainly reviews the pathophysiological mechanisms of pyroptosis in MIRI and the effect of related therapeutic drugs on pyroptosis and its application in the prevention and treatment of MIRI.
作者 陈艳丽 李秀芬(综述) 王凯阳 帕尔哈提·吐尔逊(审校) CHEN Yan-li;LI Xiu-fen;WANG Kai-yang;PAERHATI Tuerxun(The Fourth Clinical Medical College,Xinjiang Medical University,Urumqi 830000,China;Department of Cardiovascular Medicine,Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University,Urumqi,830000,China)
出处 《微循环学杂志》 2023年第1期90-96,共7页 Chinese Journal of Microcirculation
基金 新疆维吾尔自治区自然科学基金资助项目(2022D01C165)。
关键词 细胞焦亡 心肌缺血再灌注损伤 靶向药物 Pyroptosis Myocardial ischemia-reperfusion injury Targeted drugs
  • 相关文献

参考文献11

二级参考文献118

  • 1Abe Y, Hashimoto S, Horie T (1999) Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 39:41-47.
  • 2Arends YM, Duyckaerts C, Rozemuller JM, Eikelenboom P, Hauw JJ (2000) Microglia, amyloid and dementia in alzheimer disease. A correlative study. Neurobiol Aging 21:39-47.
  • 3Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL, Martins RN (2009) Clearance mechanisms of Alzheimer’s amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 14:469-486.
  • 4Bharti AC, Donato N, Aggarwal BB (2003) Curcumin (diferuloylmeth-ane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171:3863-3871.
  • 5Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mul-lan MJ, Sabbagh M, Tariot PN, Group AR (2011) Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimer’s Dement 7:402-411.
  • 6Castello MA, Jeppson JD, Soriano S (2014) Moving beyond anti-amy-loid therapy for the prevention and treatment of Alzheimer’s disease. BMC Neurol 14:169.
  • 7Cole GM, Teter B, Frautschy SA (2007) Neuroprotective effects of curcumin. Adv Exp Med Biol 595:197-212.
  • 8Cox KH, Pipingas A, Scholey AB (2014) Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol pii: 0269881114552744.
  • 9Dadhaniya P, Patel C, Muchhara J, Bhadja N, Mathuria N, Vachhani K, Soni MG (2011) Safety assessment of a solid lipid curcumin particle preparation: acute and subchronic toxicity studies. Food Chem Toxicol 49:1834-1842.
  • 10Eikelenboom P, Veerhuis R (1996) The role of complement and activated microglia in the pathogenesis of Alzheimer’s disease. Neurobiol Aging 17:673-680.

共引文献320

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部